Recalls from Glenmark Pharmaceuticals Inc., USA

• Glenmark Abiraterone Acetate Tablets (opens in a new tab)
  Moderate risk, FDA, Oct 23, 2026, Labeling error
• Glenmark Pharmaceuticals Clindamycin Phosphate Foam, 1% (opens in a new tab)
  Moderate risk, FDA, Oct 1, 2026, Packaging defect
• Glenmark Azelaic Acid Gel (opens in a new tab)
  Moderate risk, FDA, Jul 28, 2026, Manufacturing problem
• Glenmark Alyacen 7/7/7 and Norethindrone and Ethinyl Estradiol Tablets (opens in a new tab)
  Moderate risk, FDA, Jun 12, 2026, Drug impurity

Data: Recall Canary (opens in a new tab)